🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

ImmuneOnco Biopharmaceuticals (Shanghai) clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with ImmuneOnco Biopharmaceuticals (Shanghai) as lead sponsor. Synced 26 Sep 2026
6Current trials
4Recruiting now
2Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

ImmuneOnco Biopharmaceuticals (Shanghai) is the lead sponsor of 6 current clinical trials in our China register. 4 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are Azacitidine and Lenalidomide. The most-studied condition is Advanced Solid Tumors.

ClinicalTrials.gov trials by status

  • Recruiting467%
  • Not yet open233%

Trials by phase

  • Phase 1233%
  • Phase 3233%
  • Phase 1/2117%
  • Phase EARLY_PHASE1117%
01

Clinical trials sponsored by ImmuneOnco Biopharmaceuticals (Shanghai)

6 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMC-003 for Injection in Healthy Postmenopausal Women
NCT07118085 · ClinicalTrials.gov ↗ · Healthy Postmenopausal Women
Phase 1 Recruiting 2025-08 China
A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors
NCT06764836 · ClinicalTrials.gov ↗ · Advanced Solid Tumors, HCC
Phase 1 Recruiting 2024-07 China
IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)
NCT06647862 · ClinicalTrials.gov ↗ · Chronic Myelomonocytic Leukemia
Phase 3 Recruiting 2024-11 China
A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary Syndrome.
NCT06788431 · ClinicalTrials.gov ↗ · Atherosclerosis
Phase EARLY_PHASE1 Recruiting 2025-03 China
A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors
NCT07170787 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Phase 1/2 Not yet open 2025-10 China
IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma
NCT07355283 · ClinicalTrials.gov ↗ · Relapsed/Refractory Follicular Lymphoma
Phase 3 Not yet open 2026-02 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in ImmuneOnco Biopharmaceuticals (Shanghai) trials

2 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in ImmuneOnco Biopharmaceuticals (Shanghai) trials

6 conditions
Advanced Solid Tumors2Healthy Postmenopausal Women1HCC1Chronic Myelomonocytic Leukemia1Atherosclerosis1Relapsed/Refractory Follicular Lymphoma1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China64

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Advanced Solid Tumors

SponsorTrials
Sichuan Kelun-Biotech Biopharmaceutical9
Jiangsu HengRui Medicine7
Suzhou Suncadia Biopharmaceuticals7
Shanghai Hengrui Pharmaceutical6
Bristol-Myers Squibb5
MediLink Therapeutics (Suzhou)5
Hangzhou Zhongmei Huadong Pharmaceutical5
Hansoh BioMedical R&D Company4
Bayer3
Vividion Therapeutics3

Sponsors with the most current trials registered for this condition.

06

Questions about ImmuneOnco Biopharmaceuticals (Shanghai) trials

How many clinical trials does ImmuneOnco Biopharmaceuticals (Shanghai) sponsor?

ImmuneOnco Biopharmaceuticals (Shanghai) is the lead sponsor of 6 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are ImmuneOnco Biopharmaceuticals (Shanghai) trials recruiting?

Yes. 4 of its 6 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is ImmuneOnco Biopharmaceuticals (Shanghai) testing?

Its current trials name 2 drugs and biologicals as interventions. The most frequent are Azacitidine (1) and Lenalidomide (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.